Atreca Inc (FRA:0C1)
€ 0.0435 -0.0715 (-62.17%) Market Cap: 2.93 Mil Enterprise Value: -15.66 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 0/100

Atreca Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 13, 2022 / 06:30PM GMT
Release Date Price: €1.84
Unidentified Analyst

Good afternoon, everyone. Thanks for joining our next presentation. My name is [Lander]. I'm a research associate at H.C. Wainwright. We're pleased to have you with us today. And it is now my pleasure to introduce our next presenter. Please join me in welcoming Tito Serafini, Chief Strategy Officer and Founder of Atreca, a clinical stage biopharmaceutical company focused on developing cancer immunotherapies.

Tito, welcome. And I'll turn it over to you.

Tito Serafini
Atreca, Inc. - Chief Strategy Officer

Thank you very much for inviting us today, and I'm very happy to present here today at the H.C. Wainwright Conference. So in the interest of time, I will skip through.

Here's our forward-looking statements disclaimer. The entire presentation I'm using today is available on our website as well, and I will skip through some of the company highlights here in the interest of time to focus on what it is we do, why it works, and what our first view of our pipeline assets to give folks -- give you a very good idea, I hope.

What

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot